Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Describe the efficacy and safety of Orelabrutinib in the treatment of HP-positive gastric MALT lymphoma
Trial Details
- NCT ID
- NCT06228963
- Phase
- PHASE2
- Sponsor
- Fudan University
- Status
- RECRUITING
- Cancer Type
- Marginal Zone Lymphoma Lymphoma
- Interventions
- Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib
- Triple therapy for eradication of Helicobacter Pylori
- Locations (sample)
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
- Age ≥ 18 years old
- Histologically confirmed gastric mucosa-associated lymphoid tissue (MALT) lymphoma;
- Current infection with Helicobacter pylori (Hp): Diagnosis can be made if any of the following criteria are met: a) Positive result in at least one…
- ECOG (Eastern Cooperative Oncology Group) performance status 0-2.
For full eligibility, visit ClinicalTrials.gov.